medical device investing NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
medical device investing NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
medical device investing NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery Meeting
medical device investing NeuroPace Announces FDA Approval of ECoG Assistant, Advancing AI-Driven Epilepsy Care
medical device investing NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
medical device investing NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study Results in Neurology and NAUTILUS Presentation at AAN 2026
medical device investing NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
medical device investing NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
medical device investing NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
medical device investing NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
medical device investing NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
QIMC Reports Record 23.5% Natural Hydrogen Within the First 300 Metres of Ongoing DDH-26-05 and Observations Consistent with Free Gas at Bennett Hill at 164 Metres
